Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982471 · ClinicalTrials.gov registry record
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 36
- Enrollment target
NCT04982471: Clinical Trial study, sponsored by Celgene.
NCT04982471 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04982471 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
Primary Outcome
Describe patient characteristics in community and academic settings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2023-08-03 |
Why NCT04982471 stopped before completion
NCT04982471 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04982471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04982471 about?
NCT04982471 is a clinical study titled "Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study". The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
What is the current status of trial NCT04982471?
This trial is currently terminated. The enrollment target is 36 participants. The study started on 2021-11-03. Estimated completion is 2023-08-03.
Who is sponsoring clinical trial NCT04982471?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI